ANNX · NASDAQ · Biotechnology

Annexon (ANNX)

Develops C1q-targeted therapies for complement-mediated diseases of the body, eye, and brain.

$4.96
Pre-market+0.02 (+0.41%)
At close$4.94(+0.92%)

Something off on this page? Send us feedback.

Next report
Nov 9, 2026
in 67 days
EPS estimate
−$0.26
Revenue estimate
$3.5M
Fiscal quarter
Q3 FY26

EPSReportedEstimate

May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported−$0.37−$0.34−$0.37−$0.28−$0.23−$0.28−$0.28Pending
Estimate−$0.30−$0.36−$0.34−$0.32−$0.30−$0.24−$0.23−$0.26
Surprise−23.3%+5.6%−8.8%+12.5%+23.3%−17.2%−21.7%

RevenueReportedEstimate

May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
ReportedPending
Estimate$3.3M$5.5M$6.5M$6.5M$3.5M
Surprise

History

DateEstimateReportedSurprise
Nov 2026−$0.26
Aug 2026−$0.23−$0.28−21.7%
Aug 2026−$0.24−$0.28−17.2%
May 2026−$0.30−$0.23+23.3%
Mar 2026−$0.32−$0.28+12.5%

The latest year is open to everyone — the 31 quarters behind it read with an account.

Sign in
Nov 2025
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
May 2022
Mar 2022
Nov 2021
Aug 2021
May 2021
Mar 2021
Nov 2020
Sep 2020
Jul 2020
Dec 2019
Sep 2019
Jun 2019
Mar 2019
Dec 2018
Sep 2018
Jun 2018
Mar 2018
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 9, 2026−$0.26$3.5M
Aug 13, 2026−$0.23−$0.28−21.7%$6.5M−1.3%
Aug 12, 2026−$0.24−$0.28−17.2%$6.5M−0.2%
May 7, 2026−$0.30−$0.23+23.3%$5.5M+3.1%
Mar 30, 2026−$0.32−$0.28+12.5%$3.3M+11.7%

The latest year is open to everyone — the 31 quarters behind it read with an account.

Sign in
Nov 10, 2025
Aug 14, 2025
May 12, 2025
Mar 3, 2025
Nov 14, 2024
Aug 12, 2024
May 13, 2024
Mar 26, 2024
Nov 13, 2023
Aug 7, 2023
May 8, 2023
Mar 6, 2023
Nov 3, 2022
Aug 8, 2022
May 9, 2022
Mar 1, 2022
Nov 9, 2021
Aug 16, 2021
May 17, 2021
Mar 25, 2021
Nov 16, 2020
Sep 8, 2020
Jul 24, 2020
Dec 31, 2019
Sep 30, 2019
Jun 30, 2019
Mar 31, 2019
Dec 31, 2018
Sep 30, 2018
Jun 30, 2018
Mar 31, 2018